Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
Stereotaxis (NYSE:STXS), Inc. (NYSE American:STXS), a medical technology company with a market capitalization of $205 million, announced Thursday that it expects to report revenue for the second quarter of 2025 in the range of $8.5 million to $8.8 million. This preliminary figure represents an estimated 15% sequential increase over the first quarter of 2025 and a 90% increase compared to the same period in 2024. The company cited growth in both recurring and system revenues. According to InvestingPro data, the stock has shown strong momentum with a 15% return over the past six months, though analysts note the company isn’t expected to be profitable this year.
Gross margins for both system and recurring revenue in the second quarter are anticipated to be at or slightly above levels reported in the first quarter of 2025. GAAP operating expenses for the period are projected to be between $8.2 million and $8.8 million.
The preliminary financial results are based on the company’s current expectations and are subject to adjustment following the completion of standard quarter-end review procedures. Stereotaxis stated that it will report full financial results for the period ending June 30, 2025, with an earnings call scheduled for August 2025. Analyst price targets for the stock currently range from $4 to $5, suggesting potential upside from the current price of $2.39.
This information is based on a statement from the company’s recent SEC filing.
In other recent news, Stereotaxis Inc. reported its financial results for the first quarter of 2025, meeting Wall Street expectations with an earnings per share (EPS) of -0.07 and achieving revenue of $7.5 million, which surpassed the forecast of $6.83 million. This represents a 9% year-over-year revenue growth, with significant contributions from both system and recurring revenues. The company also announced a registered direct offering, securing approximately $12.5 million through the sale of common stock, which will be used to accelerate product commercialization and for research and development. Additionally, Stereotaxis received European approval for its MAGIC RF Ablation Catheter, marking a significant milestone in their product expansion strategy. Shareholders of Stereotaxis approved the election of two Class III directors and ratified Ernst & Young LLP as the company’s independent auditor for fiscal year 2025. Analyst firm Lake Street Capital Markets served as the exclusive placement agent for the recent stock offering. These developments reflect ongoing strategic initiatives and investor confidence in Stereotaxis’ direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.